What is NeoGenomics's stock-based comp?

NeoGenomics (NEO) reported stock-based comp of $9.64M in Q1 2026.

How has NeoGenomics's stock-based comp changed year-over-year?

NeoGenomics's stock-based comp decreased by 10.4% year-over-year, from $10.75M to $9.64M.

What is the long-term trend for NeoGenomics's stock-based comp?

Over 4 years (2021 to 2025), NeoGenomics's stock-based comp has grown at a 16.5% compound annual growth rate (CAGR), from $22.46M to $41.32M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

NeoGenomics NEO Stock-Based Comp

Stock-Based Comp at other companies

Labcorp HoldingsLH

$31.7M-3.4%

Quest DiagnosticsDGX

$20M-9.1%

Personalis, Inc.PSNL

$2.55M+15.1%

Guardant HealthGH

$47.61M+26.1%

Natera, Inc.NTRA

$95.11M+22.2%

Tempus AI, Inc.TEM

$52.71M+129%

Segments

By segment

See full

Reportable Segment$9.64M-10.4%

Other financials

Income statement

See full

Revenue$186.7M+11.1%

Gross profit$80.9M+10.4%

Operating income-$18.2M+34.4%

Net income-$17.1M+34.0%

EPS (diluted)-$0.13+35.0%

Balance sheet

See full

Cash & equivalents$146.1M-57.8%

Total debt$66.3M+5.3%

Total equity$828.8M-6.7%

Total assets$1.3B-15.9%

Cash flow

See full

Operating cash flow-$8.1M+67.9%

CapEx$5.0M+11.1%

Free cash flow-$13.1M+56.0%

Valuation

See full

Market cap$1.68B-21.0%

Enterprise value$1.6B-5.6%

P/S2.3×-0.9×

Profitability

See full

Gross margin43.2%-1.1pp

Operating margin-14.2%+1.1pp

Net margin-13.3%+2.4pp

FCF margin-4.9%—

Returns & leverage

See full

Return on equity-11.6%+6.2pp

Debt / equity0.1×0.0×

Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NeoGenomics's stock-based comp?: NeoGenomics (NEO) reported stock-based comp of $9.64M in Q1 2026.
How has NeoGenomics's stock-based comp changed year-over-year?: NeoGenomics's stock-based comp decreased by 10.4% year-over-year, from $10.75M to $9.64M.
What is the long-term trend for NeoGenomics's stock-based comp?: Over 4 years (2021 to 2025), NeoGenomics's stock-based comp has grown at a 16.5% compound annual growth rate (CAGR), from $22.46M to $41.32M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.